Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
NCT04857983Phase 3Completed
- Sponsor
- University of California, San Diego
- Start
- Jul 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of memantine in schizophrenia, schizoaffective disorder, sponsored by University of California, San Diego. Started Jul 2021; status: completed.
02
Drugs
memantine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT04857983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857983.